Related Experiment Video
Updated: Jan 17, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Where next for potassium binders in hemodialysis?
Katherine Scovner Ravi1, Finnian R Mc Causland1
1Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
Insights
Sodium zirconium cyclosilicate improved potassium control in hemodialysis patients but did not reduce cardiovascular events. The DIALIZE-Outcomes trial was terminated early due to low event accrual and high discontinuation rates.
Area of Science:
- Nephrology
- Cardiology
- Clinical Trials
Background:
- Hyperkalemia is a common complication in hemodialysis patients, increasing mortality risk.
- Effective management of hyperkalemia is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of sodium zirconium cyclosilicate, an oral potassium binder, in reducing cardiovascular events in hemodialysis patients.
- To assess the safety and tolerability of sodium zirconium cyclosilicate in this population.
Main Methods:
- The DIALIZE-Outcomes trial was a prospective study investigating sodium zirconium cyclosilicate versus placebo.
- The study was terminated early due to low event accrual and high medication discontinuation rates.
Main Results:
- No significant difference in cardiovascular outcomes was observed between the sodium zirconium cyclosilicate and placebo groups.
- Sodium zirconium cyclosilicate demonstrated improved control of serum potassium levels.
Conclusions:
- Despite achieving better potassium control, sodium zirconium cyclosilicate did not show a reduction in cardiovascular events in the DIALIZE-Outcomes trial.
- Trial limitations included early termination and high discontinuation rates, necessitating further research.
Abstract:
Patients on hemodialysis frequently experience hyperkalemia, a condition linked to arrhythmia and mortality. The DIALIZE-Outcomes trial was designed to investigate whether the oral potassium binder, sodium zirconium cyclosilicate, could reduce cardiovascular events. The trial was terminated early because of low event accrual and high rates of medication discontinuation. From the available data, no difference in outcomes was observed, despite better potassium control. We discuss the strengths and limitations of the trial and highlight considerations for future studies.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Acute Kidney Injury V: Interprofessional Care
Heart Failure Drugs: Diuretics
Chronic Kidney Disease III: Interprofessional Care
Hemodialysis III: Nursing Management
Acute Kidney Injury VI: Nursing Management

